Semaglutide for one year: what the real data says about long-term results

What's this video probably claiming?

Based on the caption and hashtag context, this creator is sharing a one-year anniversary update on semaglutide therapy through a telehealth platform. The likely narrative: sustained weight loss, a dramatic reduction in what she calls "food noise" and "constant anxiousness," and an overall sense of finally being in control around eating. The #weightlosssurgery hashtag alongside #weightlossjourney suggests she may also have had bariatric surgery (VSG is in her handle, short for vertical sleeve gastrectomy), which would make this a combination case rather than semaglutide alone. That detail matters enormously for interpreting her results and is almost certainly missing from the framing. Transformation content on TikTok rarely leads with that kind of nuance, and this caption does not appear to be an exception.

What does the science actually show?

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that semaglutide 2.4 mg weekly produced a mean weight reduction of 14.9% over 68 weeks in adults with obesity. That is a real and clinically meaningful number. On the "food noise" question, a secondary analysis from STEP trials confirmed reductions in appetite and cravings, and a 2023 paper by Rubino et al. in Obesity explored how GLP-1 agonists appear to reduce the preoccupation with food that many patients describe. However, the anxiety framing is murkier. Semaglutide is not approved or studied as an anxiolytic. Some patients report mood improvements likely secondary to metabolic changes and reduced binge-restrict cycles, but that is not the same as a direct anti-anxiety mechanism, and conflating the two in a short video is a meaningful gap.

Where does the social media noise diverge from clinical reality?

One-year transformation content has a survivor bias problem that almost no creator addresses. The STEP 4 trial (Rubino et al., 2021, JAMA) showed that patients who discontinued semaglutide regained approximately two-thirds of their lost weight within one year. The drug works while you take it. Presenting a one-year success story without acknowledging that this is an ongoing medical therapy, not a completed intervention, misleads viewers who may think a year of treatment equals a permanent fix. Additionally, if this creator had VSG prior to or during semaglutide treatment, her results are not generalizable to people using semaglutide alone. Bariatric surgery independently produces 25-30% total body weight loss, and the additive effect makes attribution nearly impossible without controls. Telehealth partnership disclosures also raise the question of whether this is an organic testimonial or compensated promotion.

What should you actually know?

Semaglutide is one of the most rigorously studied weight management drugs in recent history, and a one-year result can absolutely be real. But a few things the video almost certainly skips: side effects including nausea, vomiting, and gastroparesis risk are common enough that 4.5% of participants in STEP 1 discontinued due to GI events. Muscle mass loss alongside fat loss is a documented concern with rapid weight reduction on GLP-1 agonists, with Bikou et al. (2023, Nutrients) noting the importance of resistance training and protein intake to offset lean mass reduction. The "food noise" reduction many patients describe is experientially consistent with what researchers observe, but individual response varies substantially. Anyone considering semaglutide should have this conversation with a licensed provider who reviews their full medical history, not a 60-second TikTok video from someone whose surgery history may be doing a lot of the work here.